The Food and Drug Administration has approved a higher dose version of Novo Nordisk's weight loss injection, Wegovy, as part of a strategy for the company to regain market share from its chief rival, Eli Lilly. The higher dose is expected to be launched in April to compete with Lilly's obesity drug Zepbound, which has proven significantly more effective at promoting weight loss than the standard 2.4-milligram dose of Weguidance. The high-dose Wegovys helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial. The approval marks the first approval of a GLP-1 treatment under the FDA's new national priority voucher plan.